Ocular FIP treatment gains clearer footing for veterinarians

CURRENT FULL VERSION: Ocular feline infectious peritonitis is moving from a near-hopeless diagnosis toward a treatable one, and that’s the core message behind VETgirl’s recent podcast, “Ocular FIP - A New Vision For Treatment.” The episode reflects a broader evolution in feline medicine: antivirals such as GS-441524 and remdesivir have changed the prognosis for many cats with FIP, including some with ocular involvement, where preserving vision and controlling inflammation are central concerns. VETgirl’s review also serves as a reminder that ocular disease is not a niche footnote in FIP: ocular and neurologic involvement are seen far more often in dry than wet disease, and in some cats uveitis is the dominant presenting complaint rather than an incidental finding. In the U.S., that clinical shift has been supported by improved access since June 1, 2024, when compounded oral GS-441524 became available through veterinary prescription under FDA’s stated enforcement-discretion framework for patient-specific use. (fda.gov)

The backdrop here is years of pent-up demand. FIP was long regarded as almost uniformly fatal once clinical signs developed, pushing many pet parents toward unregulated gray-market antivirals. FDA said in 2024 that compounded GS-441524 products remain unapproved animal drugs and are not technically “legal,” but the agency also stated it does not intend to enforce approval requirements when veterinarians prescribe compounded GS-441524 for a specific cat under the conditions in Guidance for Industry #256. That distinction matters operationally for practices: access improved, but prescribing still sits inside a specific regulatory framework, not a full approval pathway. (fda.gov)

The evidence base is also maturing. A 2025 systematic review of GS-441524 literature from 2018 to 2024 reported an overall treatment success rate of 84.6% and noted that best outcomes were associated with doses in the 5 to 10 mg/kg once-daily range, adjusted for disease form and for neurologic or ocular signs. The review also emphasized that more severe presentations may need higher dosing and that randomized controlled trials are still needed to establish presentation-specific protocols. That aligns with the broader clinical message coming through recent VETgirl education: response rates for FIP are now commonly cited in the roughly 85% to 90% range, but success depends heavily on matching dose intensity and duration to presentation. (pubmed.ncbi.nlm.nih.gov)

For ocular disease specifically, one of the most relevant newer papers is a 2025 observational case series on cats with ocular involvement treated with remdesivir alone or in combination with GS-441524. PubMed’s record and figure captions describe resolution of lesions including panuveitis, posterior uveitis, retinal hemorrhage, keratic precipitates, hyphema, and rubeosis iridis after antiviral treatment courses. VETgirl’s discussion usefully framed what clinicians should be looking for before treatment even starts: anterior chamber findings can include keratic precipitates, iris color change, dyscoria or anisocoria, hyphema, hypopyon, or fibrinous exudate, while posterior segment findings may include tapetal or non-tapetal retinal lesions, vascular tortuosity, retinal detachment, and perivascular cuffing. These signs may be unilateral or bilateral, and sometimes they are the first clue to underlying systemic infection. That’s clinically important because it moves the conversation beyond survival to restoration of ocular comfort and, in at least some cases, useful vision. (pubmed.ncbi.nlm.nih.gov)

Broader FIP treatment studies reinforce that signal. A Frontiers in Veterinary Science study comparing GS-441524 and molnupiravir in 118 cats used higher dosing when neurologic and/or ocular signs were present, with treatment continued for 84 days. Among survivors, neurologic and ocular signs resolved in all but one cat with persistent seizures, and laboratory abnormalities generally normalized within six to seven weeks. In that cohort, most deaths occurred within the first 10 days of treatment, suggesting the earliest treatment window remains especially consequential. (public-pages-files-2025.frontiersin.org)

Recent discussion around dosing and duration is also becoming more nuanced. In another VETgirl podcast reviewing a 2025 JSAP paper on high-dose induction therapy with remdesivir/GS-441524, Dr. Lee highlighted a practical tension many clinicians know well: cats often look dramatically better within the first week of treatment, but clinical improvement does not necessarily mean viral clearance, especially in harder-to-penetrate sites such as the eyes and central nervous system. That podcast pointed to growing interest in using objective markers, including serum amyloid A, alpha-1 acid glycoprotein, and albumin:globulin ratio trends, to help decide when treatment can safely stop rather than relying on appearance alone.

Expert commentary remains appropriately cautious about how fast protocols should change. Infectious disease specialist Dr. Scott Weese, writing on Worms & Germs about a 2024 randomized study of shorter-course therapy, said 42-day treatment may be reasonable in some cats with effusive FIP, but he warned against broadly extrapolating those findings to neurologic or ocular FIP, where evidence is thinner and severity is often greater. He also underscored a point many clinicians will recognize immediately: results from pharmaceutical-grade or legitimate compounded products shouldn’t be assumed to apply to black-market formulations. (wormsandgermsblog.com)

Diagnosis, meanwhile, remains one of the trickiest parts of real-world FIP care. As recent VetGirl and dvm360 educational discussions have emphasized, clinicians often work with a presumptive diagnosis rather than a single definitive test result. That makes pattern recognition especially important: FIP often affects young cats, especially those from multi-cat environments, and stems from mutation of feline enteric coronavirus in a minority of infected cats, leading to macrophage-associated spread and vasculitis. In practice, ocular findings paired with compatible systemic clues, inflammatory clinicopathologic changes, effusion characteristics, or neurologic signs can be enough to move FIP much higher on the list and justify urgent discussion of treatment options.

Why it matters: For veterinary professionals, the ocular FIP story is now less about whether treatment is possible and more about how to diagnose early, counsel clearly, and choose protocols carefully. Ocular findings such as anterior or posterior uveitis, retinal changes, hyphema, keratic precipitates, anisocoria, or iris color change may be part of the first presentation, and they can coexist with neurologic or systemic disease. That means general practitioners, emergency clinicians, internists, and ophthalmologists all have a role in identifying likely FIP quickly and setting expectations with pet parents around duration, monitoring, cost, and the possibility of dose escalation. It also means practices need to stay precise on sourcing and compliance, because the quality concerns documented with unregulated antivirals aren’t theoretical. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next phase will likely center on protocol refinement for ocular and neurologic cases, including whether shorter treatment durations can be used safely in selected cats, how often high-dose induction, twice-daily or escalated dosing is needed, and whether objective biomarkers can help determine when treatment can stop without increasing relapse risk. Comparative data may also shift some clinicians toward alternatives such as molnupiravir in specific scenarios. For now, the field is moving toward more standardized, evidence-based care, but ocular FIP still sits in the part of that curve where clinical judgment matters a great deal. (wormsandgermsblog.com)